





● Appreciate the significance of addressing smoking cessation
● Learn a brief interventional model for cessation counseling
● How to structure a quit plan




● Learn practical tips and hear sample language 







Mr. M is a 57 yo M with DM2, HLD, COPD who presents to establish care. 
Your MA marked him as a current smoker.
You learn he has smoked for 20 years, 1 pack a day.  
You are already running 30 minutes behind and have another patient roomed. 
Do you travel down the road of smoking cessation?
Tobacco is the 
leading preventable 
cause of disease, 





20% of US adults 
used tobacco (50 
million). 
14% of smoked cigarettes
6% used e-cigarettes
70% of cigarette 
smokers see a 
clinician annually
70% of adults who smoked 
reported they wanted to stop 
Only 30% of tobacco users 







Disparities in Tobacco Use
Communication Models
Brief Assessment + Brief Intervention
● The 5A’s
● “Ask, Advise, Refer”
● Motivational Interviewing 
5 A’s of Smoking Cessation
Ask about tobacco use at every visit
Advise to quit in a clear and personalized manner
Assess willingness/readiness to quit
Assist with the quit attempt 
Arrange follow-up and support
Ask
All patients about tobacco use at every visit
Identify/verify use
Treat as a “vital sign”
“Do you use tobacco products, for 
example cigarettes or 
e-cigarettes?”
5 A’s of Smoking Cessation
Ask about tobacco use at every visit
Advise to quit in a clear and personalized manner
Assess willingness/readiness to quit
Assist with the quit attempt 





“ Quitting is the most important thing you can 
do for your health. As someone who cares 
about you and your health, I’d like to help you 
quit.”
“As your physician, I need you to know that 
quitting smoking is the most important thing 
you can do to protect your health now and in 
the future. The clinic staff and I can help you.”
“While smoking less is better, occasional or 
light smoking is still dangerous. Our ultimate 
goal should be to quit.”
“Continuing to smoke makes your asthma 
worse and quitting may drastically improve 
your health.”
“I know your a busy parent. Quitting smoking 
may reduce the number of ear infections and 
doctor’s visits your child has.”
5 A’s of Smoking Cessation
Ask about tobacco use at every visit
Advise to quit in a clear and personalized manner
Assess willingness/readiness to quit
Assist with the quit attempt 




“Would you be willing to quit within the 
next month if I provide help for you?”
“Quitting can be hard and it often takes 
several tries to quit successfully. 
Would you like to try again now? ”
“I’d like to hear your thoughts about 
quitting?”

Case 1: Mr. M
Mr M has actually been considering quitting smoking since he got sick with 
pneumonia this year. He is willing to try quitting and would like your help.
Where do you start?
5 A’s of Smoking Cessation
Ask about tobacco use at every visit
Advise to quit in a clear and personalized manner
Assess willingness/readiness to quit
Assist with the quit attempt 
Arrange follow-up and support
Assist




1. Smoking dependence 
● How much are you smoking?
● How soon after waking up do you 
smoke?
Med dosing
2. Prior quit attempts
● Have you been able to quit before?
● What has worked for you in the past?
Quit plan
3. Potential Challenges
● What was difficult for you?




● Why do you want to quit?
Document and re-address on follow-up
Quit Plan
STAR protocol:
- Set a quit date (or taper plan)
- Tell family, friends, co-workers; ask for their support
- Anticipate challenges 
- Remove tobacco products from environment
Cold Turkey vs Taper 
● Some evidence abrupt stop = higher success
● Individualized
- Prior attempts
- Degree of dependence
● Ask patient preference! 
“What do you think will work for you?”
“What would you feel comfortable with?”
Case 1: Mr. M
Mr. M has never had any prior quit attempts. He wants to quit in the next 2 weeks. 
When you bring up medications, he says he’s interested in hearing his options. 
How do you counsel him on pharmaceutical treatment? 
Medication











General approach: combination therapy of long acting + short acting 
“Basal- Bolus” or “Controller-rescue”
Nicotine Patch
MOA: Long acting NRT. Delivers baseline degree 
of nicotine to blunt withdrawal symptoms.
Dosing: 7mg, 14mg, 21 mg
- >10 cig/day: 21 mg
- <10 cig/day: 14mg
- <5 cig/day: start with short-acting
*Common to underdose, be liberal
Duration: 3 months - 1 year
Taper: non-exact science
Apply in AM, change daily
Leave on if still smoking
Side Effects:
Skin irritation→ apply to different area daily
Vivid dreams (20%) → always warn, can remove 
overnight
Short Acting Nicotine Replacement Therapy (NRT)
MOA: Delivers faster burst of nicotine, controls cravings 
Which one works best?
- 2018 Meta-analysis (136 studies, n= 64,000)
- Comparing different types of NRT
- Results: all forms effective
- Overall, increased quit rate by 50%
Nicotine Mini Lozenge
Used instead of patch for <5 cigs per day 
Compared to traditional lozenge:
- More palatable
- Less GI distress
- Dissolves better -> rapid serum levels
Dose: 2mg, 4mg
- If smokes within 30 mins waking : 4mg
- If smokes later: 2mg
Counseling:
- Don’t chew. Place in mouth. Let dissolve.
- Get ahead of cravings! (Takes 1 hour to 
affect serum nicotine level)





- If smokes within 30 mins waking : 
4mg
- If smokes later: 2mg
Frequency
- Every 1-2 hours + with urge to smoke
- Up to 24 pieces/day
- Stay ahead of cravings with 
scheduled doses
Counseling:
- Absorbed through buccal mucosa
- Chew sparingly 
- Park for total ~20 min
- Avoid soda, coffee, alcohol (needs 
alkaline environment)
- Avoid with dentures
- OTC
SE: GI irritation if swallowed
Less used NRT (require prescriptions)
Nasal Spray
- Con: Least tolerated, nasal/throat 
irritation
- Pro: Fastest acting 
Inhaler
- Mimics hand-to-mouth habit
- Puff, don’t inhale (uses buccal 
mucosa)
Nicotine Replacement Therapy-  Summary Points
→ Combination NRT is most successful
- Single NRT : doubles success rate 
- Combination NRT: triples success 
→ Use basal-bolus method
→ Warn about vivid dreams (all),  skin irritation (patch)
→ Lozenge and gum: absorbed through cheek, use 4mg dose if smokes 
within 30 mins of waking
→ Underdosing is common. 
Case 1: Mr. M
- Started on 21 mg patch (smokes 1 ppd)
- Started on 4mg mini lozenge (smokes upon waking) 
On follow-up, relapsed due to stress at work.
What else can we offer him?
Medication












MOA: Nicotine antagonist and agonist
Effect: Triples chances of success  
Dosing:
- Begin starter pack 1 week before quit date
- Days 1-3: 0.5mg daily
- Days 4-7: 0.5mg BID 
- Day 8: QUIT, 1mg BID
- Refill 1mg BID pack
Duration: 3-6 months, can take longer
SE: 
- Nausea- improves, take w/ food
- Vivid dreams/insomnia- avoid before bed
- Anxiety, irritability 
Chantix and Mental Health
EAGLES Trial
- Lancet 2016 RCT, n=2000
- Randomized to varenicline, bupropion, 
patch, placebo
- 50% patients w/ stable psych conditions
- Result: No difference in psychiatric AE 
among groups
→ BLACK BOX WARNING REMOVED in 2016!
A stable psychiatric condition in NOT a contraindication to any smoking 
cessation medication. 
Sustained Release Bupropion 
Wellbutrin SR, Zyban
MOA: Neuronal reuptake inhibitor of NE and 
dopamine
Effect: Doubles chances of quitting
For coexisting depression, weight gain 
concern
Dose:
- Start 1 week before quit date
- Days 1-3: 150mg daily
- Day 4: 150mg bid
Duration: 3 mo - year
SE:
- Lowers seizure threshold 





Non-NRT Therapies -  Summary Points
→ Can be used in combination (eg: varenicline + combination NRT)
→ Varenicline: 
- Most effective option (even better with NRT)
- Safe with psychiatric history
→ Bupropion
- Avoid if seizure history or threshold lowering medication
→ Start both 1 week before quit date
Electronic Cigarettes
Less toxic, not harmless
Unknown long-term effects
E-cig or Vaping Use Associated Lung Injury 
(EVALI)
Nicotine + combustion products 
(chemicals, carcinogens)
Electronic Cigarettes
2019 NEJM RCT randomized 900 ppl (e-cig or NRT)
- Given e-cig starter pack or NRT of choice
- Abstinence rates at 1 year double in e-cig group (18% vs 9%)
- 80% e-cig group still vaping 
- 9% still using NRT
Electronic Cigarettes: What do we tell our patients?
2021 USPSTF Final Recommendation Statement for Tobacco Cessation Interventions
1. Prioritize FDA approved medications first
2. Vaping = harm reduction if standard treatment failed
Electronic Cigarettes: Counseling
1. Stop combustible tobacco 
completely
A complete switch
2. Establish e-cigarette quit date 
or taper plan







Know your odds. 
Self quit: 10% success
Nicotine replacement: 20% success





5-10 lb gain is common. 
Emphasize use of mini lozenge/gum (appetite suppressant)







Go for a walk
Avoid late caffeine
Focus on a hobby, clean the 
house, call a friend
Drink more water






Avoid alcohol for the first month
Encourage those around you to 
quit/ not smoke around you
Avoid places where you buy 
tobacco, use tobacco, take a 
different route to work
Get rid of cues (lighters, ashtrays)

Case 1: Mr. M
- Avoid vaping
- Instead, add varenicline to his combination NRT (triple chance of success)
- Discussed weight gain and controlling cravings
What else can we do to increase chances of success?
5 A’s of Smoking Cessation
Ask about tobacco use at every visit
Advise to quit in a clear and personalized manner
Assess willingness/readiness to quit
Assist with the quit attempt 
Arrange follow-up and support
Arrange
Close follow-up
Refer to supplemental 
resources/counseling
● Use technology
● Know local resources
1-800-QUIT-NOW / PA Free Quitline
Phone and/or web based program
- Coaching




1. Web Intake: PA Free Quitline online, QuitLogix
2. Call 1-800-QUIT-NOW 
Smokefree.gov
SmokefreeTXT
Text QUIT to 47848
3-5 messages/day
Over 6-8 wks




Myrna Brind Center for Mindfulness
Weekly group sessions, individual 
support/coaching, medication support, 
hypnosis
$249, 3 weeks
Penn Stop: Penn’s Comprehensive 
Smoking Treatment Program 
Penn Lung Center
Temple Smoking Cessation Program 
Temple Lung Center
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